Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Stock Exchange Sci-Tech Innovation Board Medical Index, which has seen a decline of 6.84% in the past month, 2.25% in the past three months, and 3.82% year-to-date [1] - The index consists of no more than 30 listed companies in the medical field selected from the Sci-Tech Innovation Board, reflecting the overall performance of medical listed companies [1] - The index was established with a base date of December 30, 2022, and a base point of 1000.0 [1] Group 2 - The top ten weighted companies in the index include: Huatai Medical (12.68%), United Imaging (10.07%), Aibo Medical (7.84%), Yirui Technology (6.54%), Shengxiang Biology (4.89%), Nanwei Medical (4.79%), Xinmai Medical (4.59%), Haier Biomedical (4.41%), Yahui Long (3.61%), and Bairen Medical (3.46%) [1] - The index's holdings are entirely composed of companies listed on the Shanghai Stock Exchange, with a 100% market share [1] - In terms of industry composition, medical consumables account for 47.05%, medical devices for 31.91%, and in vitro diagnostics for 21.04% [1] Group 3 - The index sample is adjusted quarterly, with adjustments implemented on the next trading day following the second Friday of March, June, September, and December each year [2] - Weight factors are adjusted in accordance with the sample adjustments, which occur at the same time as the sample adjustments [2] - Special circumstances may lead to temporary adjustments to the index, such as delisting of samples or corporate actions like mergers and acquisitions [2]

Group 1 - The core viewpoint of the news is that Haier Biomedical's stock performance and financial metrics indicate a relatively low valuation compared to the industry average, despite a decline in net profit [1][3]. - As of April 28, Haier Biomedical's closing stock price was 31.02 yuan, down 2.36%, with a rolling PE ratio of 26.90 times and a total market capitalization of 9.863 billion yuan [1]. - The average PE ratio for the medical device industry is 46.40 times, with a median of 34.81 times, placing Haier Biomedical at the 64th position in the industry ranking [1][3]. Group 2 - Haier Biomedical focuses on providing comprehensive digital solutions for life sciences and healthcare, targeting pharmaceutical companies, research institutions, and various healthcare users [2]. - The company's main products include low-temperature storage boxes, automated biological sample storage systems, and various laboratory automation equipment [2]. - In 2022, Haier Biomedical received several prestigious awards and certifications, enhancing its reputation in the life sciences and medical innovation sectors [2]. Group 3 - For the fiscal year 2024, Haier Biomedical reported a revenue of 2.284 billion yuan, a slight increase of 0.13% year-on-year, while net profit decreased by 9.71% to 367 million yuan [3]. - The company's gross profit margin stands at 47.99% [3]. - The stock's PE ratio is significantly lower than the industry average, indicating potential undervaluation [3].

青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 2025 年 4 月 29 日 1 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议材料 青岛海尔生物医疗股份有限公司 2024 年年度股东大会材料目录 | 青岛海尔生物医疗股份有限公司 2024 年年度股东大会会议议程 3 | | | --- | --- | | 议案一：关于审议公司 2024 年度财务决算报告的议案 | 6 | | 议案二：关于公司 2024 年年度利润分配预案的议案 | 7 | | 议案三：关于审议公司 2024 年年度募集资金存放与使用情况专项报告的议案 ... | 9 | | 议案四：关于使用部分超募资金永久补充流动资金的议案 | 10 | | 议案五：关于公司预计 2025 年度日常关联交易的议案 | 11 | | 议案六：关于续聘会计师事务所的议案 | 12 | | 议案七：关于审议公司内部控制审计报告的议案 | 13 | | 议案八：关于公司第三届董事会 2025 年董事薪酬方案 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688139 证券简称：海尔生物 公告编号：2025-032 青岛海尔生物医疗股份有限公司关于参加2024年度科创板医疗器械行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025年4月25日(星期五)下午15:00-17:00 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于2025年04月18日（星期五）至04月24日（星期四）16:00前登录上证路演中心网站首页点 击"提问预征集"栏目或通过公司邮箱haierbiomedical@haierbiomedical.com进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）已于2025年3月29日发布公司2024年年度报告，为 便于广大投资者更全面深入地了解公司2024年度经营成果、财务状况， ...

证券代码：688139 证券简称：海尔生物 公告编号：2025-032 青岛海尔生物医疗股份有限公司 关于参加 2024 年度科创板医疗器械行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 04 月 18 日（星期五）至 04 月 24 日（星期四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 haierbiomedical@haierbiomedical.com 进行提问。公司将在说明会上对投资者 普遍关注的问题进行回答。 青岛海尔生物医疗股份有限公司（以下简称"公司"）已于 2025 年 3 月 29 日发布公司 2024 年年度报告，为便于广大投资者更全面深入地了解公司 2024 年度经营成果、财务状况，公司计划于 2025 年 04 月 25 日（星期五）15:00-17:00 参加 2024 年度科创板医疗器械行业集体 ...

附调研内容：问题一:请问公司美国收入情况,美国对等关税政策对公司有何影响? 答:公司海外业务广泛 布局于非洲、欧洲、亚太、美洲等区域,其中2024年海尔生物的美国市场收入占公司整体收入比例不足 2%。依托美国当地化体系,公司在本次加征关税前已对意向订单进行了提前备货,因此关税对公司业务的 影响有限。 面对复杂的国际形势,公司认为应对挑战的关键在于自身能力的构建。公司通过"一国一 策"策略,持续提升本地化能力以应对风险。在本土化产品布局方面,公司高度重视区域性的产品企划,例 如超能系列产品在美国能源之星排名中位居前两位,充分展现了产品优势。在产品认证方面,公司今年陆 续完善了血站、制药、医院以及实验室系列产品的认证工作,显著提升了公司在海外市场的区域竞争 力。此外,公司还在传统业务场景基础上不断拓展新用户场景,进一步拓展全球市场的布局。 问题二:公 司2024年海外市场的业务进展情况? 答:2024年,海外市场实现收入7.15亿元,同比下降8.73%,剔除太阳能 疫苗方案影响后实现双位数增长。自进入三季度以来太阳能疫苗方案订单交付速度加快,四季度实现同 比正增长,已经基本消化了订单执行周期延长对海外收入造成的扰 ...

青岛海尔生物医疗股份有限公司的主营业务是公司以创用户最佳体验，面向医药生物企业、高校科研机 构等生命科学用户和医院、疾控、血站、基层公卫等医疗卫生用户，已形成生命科学和医疗创新两大板 块，提供以智慧实验室、数字医院、智慧公共卫生、智慧用血等为代表的数字场景综合解决方案。公司 的主要产品是低温保存箱、自动化生物样本存储库、全自动细胞培养工作站、自动化液氮罐、生物安全 柜、离心机、二氧化碳培养箱、高压灭菌器、恒温恒湿箱、恒温干燥箱、生化培养箱、环境测试箱、人 工气候箱、无菌隔离器、程序降温仪、航空温控集装箱、全自动冻干机、过氧化氢消毒机、独立通气笼 具、可控冻融系统、医用冷藏箱、智能贴签机、智能分拣机、统排机、智能配液机器人、智能静配流水 线、自动发药机、全自动包药机等院内自动化用药产品。2022年公司获得国家级博士后科研工作站、中 国工业大奖、中国科技产业化促进会科学技术奖一等奖、山东省科技进步一等奖等奖项，获批山东省工 业领域优秀数据安全解决方案，公司在生命科学和医疗创新领域科创实力不断提升。目前，公司产品及 解决方案已应用于全球130余个国家和地区，并与世界卫生组织（WHO）、联合国儿童基金会 （UNICE ...

作为盈康一生旗下企业，海尔生物通过"AI+大模型应用"战略，全面赋能生命科学与医疗创新场景，标 志着其从硬件制造商向数智化场景方案服务商转型的加速推进。 聚焦场景落地：AI技术重塑医疗效率与安全 依托AI大模型与垂直场景数据的深度融合，海尔生物在多个医疗场景实现突破。 文/杨燕 在第91届中国国际医疗器械博览会（CMEF）上，海尔生物以"AI在海尔 因AI盈康"为主题，重磅发布 《中国生物样本库行业创新发展白皮书》，并推出搭载AI技术的第四代生物样本库"生命方舟"、恒昀温 湿双控医用冷藏箱等创新成果，全面展示其在AI技术驱动下的医疗生态新图景。 公司还正式发布了新一代的"AI+大模型应用"全面战略，彰显其在生命科学领域的数智化领导力。 顾向炜强调，AI的应用并非单纯的功能叠加，而是通过智能体技术重构"产品-场景-服务"的价值链条， 推动方案从"功能型"向"数智型"代际跨越。 重塑生态共建：从技术领先到标准引领 自打破国外垄断、突破超低温核心技术以来，海尔生物一直致力于以高端技术推动行业高质量发展，并 以技术创新驱动行业标准体系建设。 自2006年至今，海尔生物已连续三次牵头制定或修订《低温保存箱》国家标准，并 ...

Group 1 - TÜV Rheinland awarded Haier Biomedical the first EU MDR certificate for medical low-temperature storage devices, indicating compliance with international standards for safety and effectiveness [1] - The certification allows Haier Biomedical's products to enter the EU market and accelerates registration processes in Southeast Asia, the Middle East, and Africa [1] - The demand for medical low-temperature storage devices is increasing due to advancements in life sciences and biotechnology, driving market growth [1] Group 2 - The acquisition of the EU MDR certificate reflects Haier Biomedical's international innovation strategy and commitment to product quality and compliance [2] - As of the end of 2024, Haier Biomedical has obtained over 400 overseas certifications, including more than 200 EU CE certifications and 70 US FDA certifications [2] - The company emphasizes self-innovation and high standards to enhance its international market presence [2]

Core Insights - The integration of AI in healthcare is transforming the industry, with significant advancements showcased at the 91st China International Medical Equipment Fair (CMEF) [2][4][10] - The Chinese government is actively supporting the innovation and development of medical devices through policy reforms and financial incentives, including a special bond of 148 billion yuan [2][15] - Domestic companies are making strides in high-end medical equipment, with products that enhance precision and accessibility in healthcare [10][15][22] Group 1: AI and Medical Technology - The AI-driven medical models, such as Mindray's "Qiyuan" critical care model, can integrate patient data and provide treatment suggestions within five seconds, already implemented in several top-tier hospitals [4][10] - Haier Biomedical has launched an AI strategy with its "Kuidou" sample library model, focusing on intelligent management of biological samples [4][6] - The emergence of AI-powered solutions in blood sugar management, remote emergency care, and imaging diagnostics is pushing the medical field from "assistance" to "autonomy" [4][10] Group 2: Innovations in Medical Devices - The introduction of the "Newton 3D" intraoperative CT and surgical robot by GeRui Technology showcases advancements in precision surgery, offering real-time 3D imaging and navigation for complex procedures [13] - The ZAP-X radiation surgery robot, featuring a unique self-shielding design, is aimed at improving the safety and precision of radiation therapy for brain and head-neck tumors [15] - The launch of innovative non-invasive respiratory devices, such as the SyncFree algorithm-based respiratory machine by Yuyue Medical, highlights the shift towards home healthcare solutions [20] Group 3: Market Trends and Consumer Needs - The demand for home healthcare solutions is rising, particularly for chronic conditions like COPD and OSA, with projections indicating significant increases in patient numbers by 2025 [16][18] - The domestic hearing aid market is experiencing a transformation, with local products now competing with foreign brands due to advancements in technology and affordability [20] - The overall vitality of the domestic medical device industry is evident, as it continues to evolve towards high-quality development and innovation [22]